Gefitinib and erlotinib are first-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs) in the treatment of NSCLC patients with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.